John R Graybill1, Rosie Bocanegra, Gloria M Gonzalez, Laura K Najvar. 1. The University of Texas Health Science Center at San Antonio, Department of Medicine, Division of Infectious Diseases (7881), 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, USA.
Abstract
OBJECTIVES: AmBisome and micafungin were used alone and in combination in a series of studies designed to identify any additive or antagonistic effects of combination antifungal therapy. METHODS: Immune-suppressed mice were infected either intravenously or intranasally with Aspergillus fumigatus. Micafungin, liposomal amphotericin B or both drugs together were administered for 7 days. Parameters of efficacy included survival and tissue burden of A. fumigatus. RESULTS: Whilst each drug was effective in murine aspergillosis, additive effects were observed only in reduction of tissue burden in limited experimental conditions. No antagonism was seen. CONCLUSIONS: The present studies neither encourage nor discourage clinical use of combination therapy. Clinical trials are suggested before combined therapy is routinely adopted.
OBJECTIVES:AmBisome and micafungin were used alone and in combination in a series of studies designed to identify any additive or antagonistic effects of combination antifungal therapy. METHODS: Immune-suppressed mice were infected either intravenously or intranasally with Aspergillus fumigatus. Micafungin, liposomal amphotericin B or both drugs together were administered for 7 days. Parameters of efficacy included survival and tissue burden of A. fumigatus. RESULTS: Whilst each drug was effective in murineaspergillosis, additive effects were observed only in reduction of tissue burden in limited experimental conditions. No antagonism was seen. CONCLUSIONS: The present studies neither encourage nor discourage clinical use of combination therapy. Clinical trials are suggested before combined therapy is routinely adopted.
Authors: Carly G Dennis; William R Greco; Yseult Brun; Richard Youn; Harry K Slocum; Ralph J Bernacki; Russell Lewis; Nathan Wiederhold; Steven M Holland; Ruta Petraitiene; Thomas J Walsh; Brahm H Segal Journal: Antimicrob Agents Chemother Date: 2006-02 Impact factor: 5.191
Authors: J A Olson; J Schwartz; D Hahka; A George; R T Proffitt; J P Adler-Moore Journal: Antimicrob Agents Chemother Date: 2011-10-03 Impact factor: 5.191
Authors: Joseph M Harrison; Randolph D Glickman; Charles S Ballentine; Yolanda Trigo; Melanie A Pena; Pearl Kurian; Laura K Najvar; Neeru Kumar; Ankit H Patel; William E Sponsel; John R Graybill; William C Lloyd; Margaret M Miller; Gianmarco Paris; Fernando Trujillo; Aaron Miller; Robert Melendez Journal: Doc Ophthalmol Date: 2005-01 Impact factor: 2.379
Authors: Antigoni Elefanti; Johan W Mouton; Paul E Verweij; Athanassios Tsakris; Loukia Zerva; Joseph Meletiadis Journal: Antimicrob Agents Chemother Date: 2013-07-15 Impact factor: 5.191